Val Shilling1, Valerie Jenkins, Ivonne Solis Trapala. 1. Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School University of Sussex, Falmer East Sussex, UK. v.m.shilling@sussex.ac.uk
Abstract
BACKGROUND: A growing number of studies report cognitive impairment after chemotherapy; indeed the phenomenon of chemo-fog is now almost universally accepted. We are concerned however that there is little if any consistency in the way in which patients are classified as showing cognitive impairment or not. We aim to demonstrate that different methods of analysis produce markedly different results, making the true extent of impairment unclear. METHODS: We analysed data from 92 breast cancer patients 4 weeks post-chemotherapy and from 42 healthy controls using 7 different methods, each taken from a different research paper in the area of cognitive impairment post-chemotherapy. FINDINGS: The extent of impairment was dependent on the method of analysis. Impairment ranged from 12 to 68.5% in the chemotherapy group and from 4.8 to 64.3% in the healthy control group. INTERPRETATION: This brief report highlights the contrasting degrees of cognitive impairment calculated by using legitimate statistical methods and demonstrates the need for a collaborative effort to standardise our methods that we might better understand the phenomenon of chemo-fog.
BACKGROUND: A growing number of studies report cognitive impairment after chemotherapy; indeed the phenomenon of chemo-fog is now almost universally accepted. We are concerned however that there is little if any consistency in the way in which patients are classified as showing cognitive impairment or not. We aim to demonstrate that different methods of analysis produce markedly different results, making the true extent of impairment unclear. METHODS: We analysed data from 92 breast cancerpatients 4 weeks post-chemotherapy and from 42 healthy controls using 7 different methods, each taken from a different research paper in the area of cognitive impairment post-chemotherapy. FINDINGS: The extent of impairment was dependent on the method of analysis. Impairment ranged from 12 to 68.5% in the chemotherapy group and from 4.8 to 64.3% in the healthy control group. INTERPRETATION: This brief report highlights the contrasting degrees of cognitive impairment calculated by using legitimate statistical methods and demonstrates the need for a collaborative effort to standardise our methods that we might better understand the phenomenon of chemo-fog.
Authors: Catherine M Bender; John D Merriman; Susan M Sereika; Amanda L Gentry; Frances E Casillo; Theresa A Koleck; Margaret Q Rosenzweig; Adam M Brufsky; Priscilla McAuliffe; Yehui Zhu; Yvette P Conley Journal: Oncol Nurs Forum Date: 2018-05-01 Impact factor: 2.172
Authors: Brian D Gonzalez; Heather S L Jim; Margaret Booth-Jones; Brent J Small; Steven K Sutton; Hui-Yi Lin; Jong Y Park; Philippe E Spiess; Mayer N Fishman; Paul B Jacobsen Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 44.544
Authors: Charissa Andreotti; James C Root; Sanne B Schagen; Brenna C McDonald; Andrew J Saykin; Thomas M Atkinson; Yuelin Li; Tim A Ahles Journal: Psychooncology Date: 2015-03-23 Impact factor: 3.894